Financial Comparison: Immune Therapeutics (OTCMKTS:IMUN) vs. Vincerx Pharma (NASDAQ:VINC)

Vincerx Pharma (NASDAQ:VINC) and Immune Therapeutics (OTCMKTS:IMUN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.

Profitability

This table compares Vincerx Pharma and Immune Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vincerx Pharma	N/A	-187.73%	-126.26%
Immune Therapeutics	N/A	N/A	-544.75%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Vincerx Pharma and Immune Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vincerx Pharma	0	0	1	0	3.00
Immune Therapeutics	0	0	0	0	N/A

Vincerx Pharma presently has a consensus price target of $5.00, suggesting a potential upside of 511.85%. Given Vincerx Pharma’s higher possible upside, equities analysts plainly believe Vincerx Pharma is more favorable than Immune Therapeutics.

Institutional and Insider Ownership

44.0% of Vincerx Pharma shares are owned by institutional investors. 22.9% of Vincerx Pharma shares are owned by insiders. Comparatively, 50.6% of Immune Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Vincerx Pharma has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, Immune Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.

Valuation and Earnings

This table compares Vincerx Pharma and Immune Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vincerx Pharma	N/A	N/A	-$40.16 million	($1.89)	-0.43
Immune Therapeutics	N/A	N/A	-$3.54 million	N/A	N/A

Summary

Vincerx Pharma beats Immune Therapeutics on 5 of the 8 factors compared between the two stocks.

About Vincerx Pharma

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

About Immune Therapeutics

Immune Therapeutics, Inc. does not have significant operations. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in October 2014. Immune Therapeutics, Inc. is based in Winter Park, Florida.